LIMITED-SAMPLING MODELS FOR ANTICANCER AGENTS

被引：49

作者：

VANWARMERDAM, LJC

HUININK, WWT

MAES, RAA

BEIJNEN, JH

机构：

[1] ANTONI VAN LEEUWENHOEK HOSP,NETHERLANDS CANC INST,DEPT MED ONCOL,1066 CX AMSTERDAM,NETHERLANDS

[2] UNIV UTRECHT,FAC PHARM,DEPT PHARMACEUT ANAL & TOXICOL,3508 TB UTRECHT,NETHERLANDS

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1994年 / 120卷 / 07期

关键词：

CHEMOTHERAPEUTIC AGENTS; LIMITED-SAMPLING MODELS; PHARMACODYNAMICS; PHARMACOKINETICS;

D O I：

10.1007/BF01240143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate population pharmacokinetic/pharmacodynamic studies, which eventually may lead to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.

引用

页码：427 / 433

页数：7

共 57 条

[1] HUMAN-PLASMA PHARMACOKINETICS OF THIOTEPA FOLLOWING ADMINISTRATION OF HIGH-DOSE THIOTEPA AND CYCLOPHOSPHAMIDE [J].

ACKLAND, SP ;

CHOI, KE ;

RATAIN, MJ ;

EGORIN, MJ ;

WILLIAMS, SF ;

SINKULE, JA ;

BITRAN, JD .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1192-1196

[2]

ADAMSON PC, 1992, CANCER RES, V52, P521

[3]

BENNETT CL, 1987, CANCER RES, V47, P1952

[4] BAYESIAN-ESTIMATION OF DOXORUBICIN PHARMACOKINETIC PARAMETERS [J].

BRESSOLLE, F ;

RAY, P ;

JACQUET, JM ;

BRES, J ;

GALTIER, M ;

DONADIO, D ;

JOURDAN, J ;

ROSSI, JF .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 29 (01) :53-60

[5] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

[6]

COLLINS JM, 1986, CANCER TREAT REP, V70, P73

[7]

CONLEY BA, 1989, CANCER RES, V49, P3436

[8] ADAPTIVE-CONTROL WITH FEEDBACK-STRATEGIES FOR SURAMIN DOSING [J].

COOPER, MR ;

LIEBERMAN, R ;

LAROCCA, RV ;

GERNT, PR ;

WEINBERGER, MS ;

HEADLEE, DJ ;

KOHLER, DR ;

GOLDSPIEL, BR ;

PECK, CC ;

MYERS, CE .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) :11-23

[9] CAN SEVERE VINCRISTINE NEUROTOXICITY BE PREVENTED [J].

DESAI, ZR ;

VANDENBERG, HW ;

BRIDGES, JM ;

SHANKS, RG .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 8 (02) :211-214

[10] AN EVALUATION OF OPTIMAL SAMPLING STRATEGY AND ADAPTIVE STUDY DESIGN [J].

DRUSANO, GL ;

FORREST, A ;

SNYDER, MJ ;

REED, MD ;

BLUMER, JL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :232-238

← 1 2 3 4 5 6 →